These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
330 related items for PubMed ID: 8196624
1. Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor beta and activin. Cárcamo J, Weis FM, Ventura F, Wieser R, Wrana JL, Attisano L, Massagué J. Mol Cell Biol; 1994 Jun; 14(6):3810-21. PubMed ID: 8196624 [Abstract] [Full Text] [Related]
2. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Attisano L, Cárcamo J, Ventura F, Weis FM, Massagué J, Wrana JL. Cell; 1993 Nov 19; 75(4):671-80. PubMed ID: 8242742 [Abstract] [Full Text] [Related]
3. Transforming growth factor (TGF-beta)-specific signaling by chimeric TGF-beta type II receptor with intracellular domain of activin type IIB receptor. Persson U, Souchelnytskyi S, Franzén P, Miyazono K, ten Dijke P, Heldin CH. J Biol Chem; 1997 Aug 22; 272(34):21187-94. PubMed ID: 9261125 [Abstract] [Full Text] [Related]
4. Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region. Wieser R, Attisano L, Wrana JL, Massagué J. Mol Cell Biol; 1993 Dec 22; 13(12):7239-47. PubMed ID: 8246946 [Abstract] [Full Text] [Related]
5. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. Yamashita H, ten Dijke P, Huylebroeck D, Sampath TK, Andries M, Smith JC, Heldin CH, Miyazono K. J Cell Biol; 1995 Jul 22; 130(1):217-26. PubMed ID: 7790373 [Abstract] [Full Text] [Related]
6. Molecular characterization of a type I serine-threonine kinase receptor for TGF-beta and activin in the rat pituitary tumor cell line GH3. Takumi T, Moustakas A, Lin HY, Lodish HF. Exp Cell Res; 1995 Jan 22; 216(1):208-14. PubMed ID: 7813622 [Abstract] [Full Text] [Related]
7. Characterization of type I receptors for transforming growth factor-beta and activin. ten Dijke P, Yamashita H, Ichijo H, Franzén P, Laiho M, Miyazono K, Heldin CH. Science; 1994 Apr 01; 264(5155):101-4. PubMed ID: 8140412 [Abstract] [Full Text] [Related]
8. Signaling activity of homologous and heterologous transforming growth factor-beta receptor kinase complexes. Vivien D, Attisano L, Wrana JL, Massagué J. J Biol Chem; 1995 Mar 31; 270(13):7134-41. PubMed ID: 7706250 [Abstract] [Full Text] [Related]
9. Identification of important regions in the cytoplasmic juxtamembrane domain of type I receptor that separate signaling pathways of transforming growth factor-beta. Saitoh M, Nishitoh H, Amagasa T, Miyazono K, Takagi M, Ichijo H. J Biol Chem; 1996 Feb 02; 271(5):2769-75. PubMed ID: 8576253 [Abstract] [Full Text] [Related]
10. Inactivation of activin-dependent transcription by kinase-deficient activin receptors. Tsuchida K, Vaughan JM, Wiater E, Gaddy-Kurten D, Vale WW. Endocrinology; 1995 Dec 02; 136(12):5493-503. PubMed ID: 7588300 [Abstract] [Full Text] [Related]
11. Determination of type I receptor specificity by the type II receptors for TGF-beta or activin. Ebner R, Chen RH, Lawler S, Zioncheck T, Derynck R. Science; 1993 Nov 05; 262(5135):900-2. PubMed ID: 8235612 [Abstract] [Full Text] [Related]
12. Formation and activation by phosphorylation of activin receptor complexes. Willis SA, Zimmerman CM, Li LI, Mathews LS. Mol Endocrinol; 1996 Apr 05; 10(4):367-79. PubMed ID: 8721982 [Abstract] [Full Text] [Related]
13. Inhibin antagonizes inhibition of liver cell growth by activin by a dominant-negative mechanism. Xu J, McKeehan K, Matsuzaki K, McKeehan WL. J Biol Chem; 1995 Mar 17; 270(11):6308-13. PubMed ID: 7890768 [Abstract] [Full Text] [Related]
14. Functional antagonism between activin and osteogenic protein-1 in human embryonal carcinoma cells. Piek E, Afrakhte M, Sampath K, van Zoelen EJ, Heldin CH, ten Dijke P. J Cell Physiol; 1999 Aug 17; 180(2):141-9. PubMed ID: 10395283 [Abstract] [Full Text] [Related]
15. Transforming growth factor-beta (TGF-beta)-induced down-regulation of cyclin A expression requires a functional TGF-beta receptor complex. Characterization of chimeric and truncated type I and type II receptors. Feng XH, Filvaroff EH, Derynck R. J Biol Chem; 1995 Oct 13; 270(41):24237-45. PubMed ID: 7592630 [Abstract] [Full Text] [Related]
16. Disruption of transforming growth factor beta signaling by a mutation that prevents transphosphorylation within the receptor complex. Cárcamo J, Zentella A, Massagué J. Mol Cell Biol; 1995 Mar 13; 15(3):1573-81. PubMed ID: 7862150 [Abstract] [Full Text] [Related]
17. TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. Piek E, Moustakas A, Kurisaki A, Heldin CH, ten Dijke P. J Cell Sci; 1999 Dec 13; 112 ( Pt 24)():4557-68. PubMed ID: 10574705 [Abstract] [Full Text] [Related]
18. Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-beta receptors in human pituitary adenomas. Alexander JM, Bikkal HA, Zervas NT, Laws ER, Klibanski A. J Clin Endocrinol Metab; 1996 Feb 13; 81(2):783-90. PubMed ID: 8636304 [Abstract] [Full Text] [Related]
19. The transforming growth factor beta type II receptor can replace the activin type II receptor in inducing mesoderm. Bhushan A, Lin HY, Lodish HF, Kintner CR. Mol Cell Biol; 1994 Jun 13; 14(6):4280-5. PubMed ID: 8196664 [Abstract] [Full Text] [Related]
20. The p21(RAS) farnesyltransferase alpha subunit in TGF-beta and activin signaling. Wang T, Danielson PD, Li BY, Shah PC, Kim SD, Donahoe PK. Science; 1996 Feb 23; 271(5252):1120-2. PubMed ID: 8599089 [Abstract] [Full Text] [Related] Page: [Next] [New Search]